Q-omics provides the consensus-scored TRBV23OR9-2 profile across patient tissues and cancer cell-line models. TRBV23OR9-2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TRBV23OR9-2 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, TRBV23OR9-2 RNA expression shows 5,604 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, PRAD, and STAD as cancer lineages where TRBV23OR9-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV23OR9-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV23OR9-2 survival associations across molecular data types. TRBV23OR9-2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV23OR9-2 RNA expression–survival associations across cancer types. High TRBV23OR9-2 expression shows unfavorable associations in MESO, KIRP, LIHC, ESCA, OV and PCPG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TRBV23OR9-2 RNA expression.
This table summarizes TRBV23OR9-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV23OR9-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV23OR9-2 shows lower tumor expression in PRAD. The PRAD box plot shows higher TRBV23OR9-2 RNA expression in normal versus tumor tissue (log2 FC = −0.103, t-test p = .019).
This table shows molecular features associated with TRBV23OR9-2 in patient tissues and cancer cell lines. In patient samples, TRBV23OR9-2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
